Skip to main content Back to Top


Hydralazine injection

Products Affected - Description

    • Hydralazine injection, X-Gen, 20 mg/mL, 1 mL vial, 25 count, NDC 39822-0500-04

Reason for the Shortage

    • Akorn had product on back order due to increased demand.
    • American Regent is not currently marketing hydralazine injection.
    • Fresenius Kabi did not provide a reason for the shortage.
    • X-Gen did not provide a reason for the shortage.

Available Products

    • Hydralazine injection, Akorn, 20 mg/mL, 1 mL vial, 25 count, NDC 17478-0934-15
    • Hydralazine injection, Fresenius Kabi, 20 mg/mL, 1 mL vial, 25 count, NDC 63323-0614-01

Estimated Resupply Dates

    • X-Gen has hydralazine 20 mg/mL 1 mL vials on back order and the company estimates a release date of late-September 2019.


Updated September 4, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 4, 2018 by Anthony Trovato, PharmD, BCPS. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins